CN113151171B - 猪肺泡巨噬细胞健康细胞系及构建方法与应用 - Google Patents
猪肺泡巨噬细胞健康细胞系及构建方法与应用 Download PDFInfo
- Publication number
- CN113151171B CN113151171B CN202110225291.4A CN202110225291A CN113151171B CN 113151171 B CN113151171 B CN 113151171B CN 202110225291 A CN202110225291 A CN 202110225291A CN 113151171 B CN113151171 B CN 113151171B
- Authority
- CN
- China
- Prior art keywords
- cell line
- virus
- porcine
- pig
- healthy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 97
- 210000001132 alveolar macrophage Anatomy 0.000 title claims abstract description 75
- 238000010276 construction Methods 0.000 title abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 27
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 229960005486 vaccine Drugs 0.000 claims abstract description 6
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 241000282898 Sus scrofa Species 0.000 claims description 58
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 claims description 23
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims description 5
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 241000188845 Porcine adenovirus Species 0.000 claims description 3
- 208000007407 African swine fever Diseases 0.000 claims description 2
- 241001673669 Porcine circovirus 2 Species 0.000 claims description 2
- 241000700568 Suipoxvirus Species 0.000 claims description 2
- 229940031567 attenuated vaccine Drugs 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 abstract description 13
- 239000013612 plasmid Substances 0.000 abstract description 12
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 238000001890 transfection Methods 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 230000009466 transformation Effects 0.000 abstract description 6
- 230000000975 bioactive effect Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 3
- 210000004322 M2 macrophage Anatomy 0.000 abstract description 2
- 230000000711 cancerogenic effect Effects 0.000 abstract description 2
- 231100000315 carcinogenic Toxicity 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 238000010187 selection method Methods 0.000 abstract description 2
- 210000003690 classically activated macrophage Anatomy 0.000 abstract 1
- 230000010287 polarization Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 description 19
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 18
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 229930182555 Penicillin Natural products 0.000 description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
- 229940049954 penicillin Drugs 0.000 description 9
- 229960005322 streptomycin Drugs 0.000 description 9
- 239000012888 bovine serum Substances 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229930182816 L-glutamine Natural products 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical group C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 101150010882 S gene Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000701386 African swine fever virus Species 0.000 description 4
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 4
- 101000869693 Homo sapiens Protein S100-A9 Proteins 0.000 description 4
- 102100032420 Protein S100-A9 Human genes 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108010009992 CD163 antigen Proteins 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- 101150082427 Tlr4 gene Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000710777 Classical swine fever virus Species 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000725681 Swine influenza virus Species 0.000 description 2
- 241000709710 Swine vesicular disease virus Species 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 101150087379 CD163 gene Proteins 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100532034 Drosophila melanogaster RTase gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000669640 Homo sapiens Mitochondrial import inner membrane translocase subunit TIM14 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102100039325 Mitochondrial import inner membrane translocase subunit TIM14 Human genes 0.000 description 1
- 241000204045 Mycoplasma hyopneumoniae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000702665 Porcine rotavirus Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20051—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110225291.4A CN113151171B (zh) | 2021-03-01 | 2021-03-01 | 猪肺泡巨噬细胞健康细胞系及构建方法与应用 |
PCT/CN2021/092592 WO2022183593A1 (zh) | 2021-03-01 | 2021-05-10 | 猪肺泡巨噬细胞健康细胞系及构建方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110225291.4A CN113151171B (zh) | 2021-03-01 | 2021-03-01 | 猪肺泡巨噬细胞健康细胞系及构建方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113151171A CN113151171A (zh) | 2021-07-23 |
CN113151171B true CN113151171B (zh) | 2024-04-05 |
Family
ID=76883722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110225291.4A Active CN113151171B (zh) | 2021-03-01 | 2021-03-01 | 猪肺泡巨噬细胞健康细胞系及构建方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113151171B (zh) |
WO (1) | WO2022183593A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113528453B (zh) * | 2021-07-07 | 2023-05-12 | 金宇保灵生物药品有限公司 | 一种永生化猪巨噬细胞株及其构建方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101668846A (zh) * | 2007-01-12 | 2010-03-10 | 伊利诺伊大学评议会 | 用于猪繁殖与呼吸综合征(prrs)病毒生长的非猿猴细胞 |
CN105793416A (zh) * | 2013-12-12 | 2016-07-20 | 英特维特国际股份有限公司 | 永生化的猪肺泡巨噬细胞 |
CN109517797A (zh) * | 2018-07-25 | 2019-03-26 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 表达猪繁殖障碍与呼吸综合症病毒受体cd163的猪永生化肺泡巨噬细胞细胞系及其应用 |
CN110195080A (zh) * | 2019-06-03 | 2019-09-03 | 山东农业大学 | 稳定表达cd163受体蛋白的重组质粒、重组慢病毒和猪肺泡巨噬细胞系及其构建方法 |
CN110577934A (zh) * | 2019-09-16 | 2019-12-17 | 中国农业科学院兰州兽医研究所 | 敲低tlr4基因猪肺泡巨噬细胞系的构建方法及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106566808A (zh) * | 2016-10-17 | 2017-04-19 | 广西大学 | 过氧化氢诱导的猪肺泡巨噬细胞系氧化应激模型的建立方法 |
-
2021
- 2021-03-01 CN CN202110225291.4A patent/CN113151171B/zh active Active
- 2021-05-10 WO PCT/CN2021/092592 patent/WO2022183593A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101668846A (zh) * | 2007-01-12 | 2010-03-10 | 伊利诺伊大学评议会 | 用于猪繁殖与呼吸综合征(prrs)病毒生长的非猿猴细胞 |
CN105793416A (zh) * | 2013-12-12 | 2016-07-20 | 英特维特国际股份有限公司 | 永生化的猪肺泡巨噬细胞 |
CN109517797A (zh) * | 2018-07-25 | 2019-03-26 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 表达猪繁殖障碍与呼吸综合症病毒受体cd163的猪永生化肺泡巨噬细胞细胞系及其应用 |
CN110195080A (zh) * | 2019-06-03 | 2019-09-03 | 山东农业大学 | 稳定表达cd163受体蛋白的重组质粒、重组慢病毒和猪肺泡巨噬细胞系及其构建方法 |
CN110577934A (zh) * | 2019-09-16 | 2019-12-17 | 中国农业科学院兰州兽医研究所 | 敲低tlr4基因猪肺泡巨噬细胞系的构建方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113151171A (zh) | 2021-07-23 |
WO2022183593A1 (zh) | 2022-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230285535A1 (en) | Recombinant Pseudorabies Virus and Vaccine Composition thereof | |
CN110218706B (zh) | 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用 | |
EP2271663A1 (en) | Novel avian astrovirus | |
CN109810976B (zh) | 猪塞内卡病毒全长感染性克隆的制备方法及应用 | |
CN110237243A (zh) | 鸭圆环病毒基因工程亚单位疫苗及其制备方法和应用 | |
CN110423269A (zh) | 一种串联优势表位的重组猪圆环病毒2型Cap蛋白及其应用 | |
CN110256539A (zh) | O型口蹄疫病毒新型基因工程亚单位疫苗 | |
CN113151171B (zh) | 猪肺泡巨噬细胞健康细胞系及构建方法与应用 | |
CN107298700B (zh) | 人工改造的PCV2 Rep蛋白、重组PCV2病毒及其应用 | |
CN112500458B (zh) | 鸡传染性法氏囊病病毒新型变异株亚单位疫苗、其制备方法及应用 | |
AU2020103776A4 (en) | Koi herpesvirus (khv) orf-149-based carbon nanotube supported nucleic acid vaccine and application thereof | |
CN111773383B (zh) | 一种o型口蹄疫亚单位疫苗及其制备方法和应用 | |
CN116376850A (zh) | B3基因型嵌合麻疹病毒减毒株和制备方法及用途 | |
CN114657154B (zh) | 一种羊传染性脓疱病毒减毒株的制备方法及其应用 | |
CN113248577B (zh) | 一种以腺病毒为载体的冠状病毒疫苗及其制备方法 | |
CN112342201B (zh) | 一种通过CRISPR/Cas9制备的猪伪狂犬病弱毒株及其应用 | |
CN112301042B (zh) | A型塞内卡病毒全长感染性cDNA克隆及其构建方法及应用 | |
CN107018955A (zh) | 一种抗猪圆环病毒2型的转基因猪 | |
CN110484515B (zh) | 一种预防FAdV-4和NDV的疫苗载体及其制备方法及应用 | |
CN104388437B (zh) | 表达o型口蹄疫病毒空衣壳的重组缺损型腺病毒及其构建方法和应用 | |
TWI328039B (zh) | ||
CN106497951B (zh) | 一种VP2融合基因、重组狂犬病病毒rHEP-rVP2株、构建方法及其应用 | |
CN110548137A (zh) | 一种基于锦鲤疱疹病毒orf149的碳纳米管载核酸疫苗及应用 | |
CN111729078B (zh) | 鸡传染性贫血病毒基因工程疫苗 | |
CN111533811B (zh) | 禽脑脊髓炎病毒新型基因工程疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Cui Xianlan Inventor after: Cui Louming Inventor after: Cui Louyao Inventor after: Lou Bing Inventor before: Cui Xianlan Inventor before: Cui Louming Inventor before: Cui Louyao Inventor before: Loubing |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230905 Address after: Room A20-804, 5th Floor, Building A, Entrepreneurship Incubation Center, No. 266 Nanhai Avenue, National High tech Industrial Development Zone, Haikou City, Hainan Province, 570100 Applicant after: Aohai Bioengineering (Haikou) Co.,Ltd. Address before: Room 708-5, C1 / F, CMC building, No.1 Yaocheng Avenue (south of Yaocheng Avenue and east of Koutai Road), Taizhou pharmaceutical hi tech Industrial Development Zone, Jiangsu Province, 225300 Applicant before: Taizhou Tianlan bioengineering partnership (L.P.) |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230919 Address after: Room 708-5, C1 / F, CMC building, No.1 Yaocheng Avenue (south of Yaocheng Avenue and east of Koutai Road), Taizhou pharmaceutical hi tech Industrial Development Zone, Jiangsu Province, 225300 Applicant after: Taizhou Tianlan bioengineering partnership (L.P.) Address before: Room A20-804, 5th Floor, Building A, Entrepreneurship Incubation Center, No. 266 Nanhai Avenue, National High tech Industrial Development Zone, Haikou City, Hainan Province, 570100 Applicant before: Aohai Bioengineering (Haikou) Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |